• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Injectable triamcinolone suspension approved for use in eye surgery

Article

The FDA has approved a formulation of triamcinolone acetonide injectable suspension 40 mg/ml (Triesence, Alcon) for visualization during vitrectomy and treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Rockville, MD-The FDA has approved a formulation of triamcinolone acetonide injectable suspension 40 mg/ml (Triesence, Alcon), a preservative-free synthetic corticosteroid, for visualization during vitrectomy and treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

The product's active ingredient, triamcinolone, has been used for many years to treat retinal disease. The new approval, however, brings ophthalmologists a sterile, preservative-free formulation of the compound specifically developed for use in the eye to treat various retinal inflammatory conditions, according to a prepared statement from Alcon.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.